Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated

Gordon Guyatt, Bruce Weaver, Lisa Cronin, Julie Ann Dooley, Ricardo Azziz

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

We examined the measurement properties of a questionnaire (PCOSQ) measuring health-related quality of life (HRQOL) in women with the polycystic ovary syndrome (PCOS). This multicenter prospective randomized placebo-controlled blinded study enrolled 393 patients with PCOS at tertiary care sites. Participants were randomized to placebo or troglitazone (150 mg/d, 300 mg/d, or 600 mg/d). At baseline (n = 393) and after 44 weeks of treatment (n = 284) the proportion of normal menstrual cycles, the free testosterone (T) level, four objective measures of facial hair growth (hair density and hair growth rate by photography, and hair diameter and hair growth rate using plucked hairs), and a subjective assessment of the degree of hirsutism, the modified Ferriman-Gallwey (F-G) score, were determined. At both visits, patients also completed the PCOSQ. Since the trial was conducted, troglitazone has been removed from the market because of toxic effects. The PCOSQ includes 26 questions (items) that address five areas of concern (domains), including emotions, body hair, body weight, fertility, and menstruation rated on a seven-point scales in which lower scores denote higher degrees of patient concern and a lower HRQOL. Cronbach's α was >0.7 for four of five domains. Factor analysis provided moderate to strong support for the five-domain structure of the PCOSQ. Cross-sectional correlations were weak with all measures but the F-G score and hair growth (r = -.46, P <. 01). The change in the F-G score showed a statistically significant (P <. 01) correlation with changes in PCOSQ hair growth (r = -.22), weight (r = -.17), infertility (r = -.20), and menstruation (r = -.20). Changes in the proportion of normal menstrual cycles correlated with change in the infertility domain (r =. 14, P <. 03) and with the change in the menstruation domain (r =. 31, P <. 001). The PCOSQ proved as responsive as the F-G, and more responsive than the objective measures of hair growth, to effects of troglitazone. Our data provides some support for the discriminative and longitudinal validity, and appreciable support for the responsiveness, of the PCOSQ.

Original languageEnglish (US)
Pages (from-to)1279-1287
Number of pages9
JournalJournal of Clinical Epidemiology
Volume57
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Polycystic Ovary Syndrome
Hair
Quality of Life
troglitazone
Menstruation
Growth
Menstrual Cycle
Infertility
Placebos
Surveys and Questionnaires
Hirsutism
Poisons
Photography
Tertiary Healthcare
Statistical Factor Analysis
Fertility
Testosterone
Emotions
Body Weight
Weights and Measures

Keywords

  • Health-related quality of life
  • Quality of life
  • polycystic ovary syndrome
  • questionnaire

ASJC Scopus subject areas

  • Epidemiology

Cite this

Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. / Guyatt, Gordon; Weaver, Bruce; Cronin, Lisa; Dooley, Julie Ann; Azziz, Ricardo.

In: Journal of Clinical Epidemiology, Vol. 57, No. 12, 01.12.2004, p. 1279-1287.

Research output: Contribution to journalArticle

Guyatt, Gordon ; Weaver, Bruce ; Cronin, Lisa ; Dooley, Julie Ann ; Azziz, Ricardo. / Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. In: Journal of Clinical Epidemiology. 2004 ; Vol. 57, No. 12. pp. 1279-1287.
@article{0d21f83455e14300ba00e1f524c8c21f,
title = "Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated",
abstract = "We examined the measurement properties of a questionnaire (PCOSQ) measuring health-related quality of life (HRQOL) in women with the polycystic ovary syndrome (PCOS). This multicenter prospective randomized placebo-controlled blinded study enrolled 393 patients with PCOS at tertiary care sites. Participants were randomized to placebo or troglitazone (150 mg/d, 300 mg/d, or 600 mg/d). At baseline (n = 393) and after 44 weeks of treatment (n = 284) the proportion of normal menstrual cycles, the free testosterone (T) level, four objective measures of facial hair growth (hair density and hair growth rate by photography, and hair diameter and hair growth rate using plucked hairs), and a subjective assessment of the degree of hirsutism, the modified Ferriman-Gallwey (F-G) score, were determined. At both visits, patients also completed the PCOSQ. Since the trial was conducted, troglitazone has been removed from the market because of toxic effects. The PCOSQ includes 26 questions (items) that address five areas of concern (domains), including emotions, body hair, body weight, fertility, and menstruation rated on a seven-point scales in which lower scores denote higher degrees of patient concern and a lower HRQOL. Cronbach's α was >0.7 for four of five domains. Factor analysis provided moderate to strong support for the five-domain structure of the PCOSQ. Cross-sectional correlations were weak with all measures but the F-G score and hair growth (r = -.46, P <. 01). The change in the F-G score showed a statistically significant (P <. 01) correlation with changes in PCOSQ hair growth (r = -.22), weight (r = -.17), infertility (r = -.20), and menstruation (r = -.20). Changes in the proportion of normal menstrual cycles correlated with change in the infertility domain (r =. 14, P <. 03) and with the change in the menstruation domain (r =. 31, P <. 001). The PCOSQ proved as responsive as the F-G, and more responsive than the objective measures of hair growth, to effects of troglitazone. Our data provides some support for the discriminative and longitudinal validity, and appreciable support for the responsiveness, of the PCOSQ.",
keywords = "Health-related quality of life, Quality of life, polycystic ovary syndrome, questionnaire",
author = "Gordon Guyatt and Bruce Weaver and Lisa Cronin and Dooley, {Julie Ann} and Ricardo Azziz",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.jclinepi.2003.10.018",
language = "English (US)",
volume = "57",
pages = "1279--1287",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated

AU - Guyatt, Gordon

AU - Weaver, Bruce

AU - Cronin, Lisa

AU - Dooley, Julie Ann

AU - Azziz, Ricardo

PY - 2004/12/1

Y1 - 2004/12/1

N2 - We examined the measurement properties of a questionnaire (PCOSQ) measuring health-related quality of life (HRQOL) in women with the polycystic ovary syndrome (PCOS). This multicenter prospective randomized placebo-controlled blinded study enrolled 393 patients with PCOS at tertiary care sites. Participants were randomized to placebo or troglitazone (150 mg/d, 300 mg/d, or 600 mg/d). At baseline (n = 393) and after 44 weeks of treatment (n = 284) the proportion of normal menstrual cycles, the free testosterone (T) level, four objective measures of facial hair growth (hair density and hair growth rate by photography, and hair diameter and hair growth rate using plucked hairs), and a subjective assessment of the degree of hirsutism, the modified Ferriman-Gallwey (F-G) score, were determined. At both visits, patients also completed the PCOSQ. Since the trial was conducted, troglitazone has been removed from the market because of toxic effects. The PCOSQ includes 26 questions (items) that address five areas of concern (domains), including emotions, body hair, body weight, fertility, and menstruation rated on a seven-point scales in which lower scores denote higher degrees of patient concern and a lower HRQOL. Cronbach's α was >0.7 for four of five domains. Factor analysis provided moderate to strong support for the five-domain structure of the PCOSQ. Cross-sectional correlations were weak with all measures but the F-G score and hair growth (r = -.46, P <. 01). The change in the F-G score showed a statistically significant (P <. 01) correlation with changes in PCOSQ hair growth (r = -.22), weight (r = -.17), infertility (r = -.20), and menstruation (r = -.20). Changes in the proportion of normal menstrual cycles correlated with change in the infertility domain (r =. 14, P <. 03) and with the change in the menstruation domain (r =. 31, P <. 001). The PCOSQ proved as responsive as the F-G, and more responsive than the objective measures of hair growth, to effects of troglitazone. Our data provides some support for the discriminative and longitudinal validity, and appreciable support for the responsiveness, of the PCOSQ.

AB - We examined the measurement properties of a questionnaire (PCOSQ) measuring health-related quality of life (HRQOL) in women with the polycystic ovary syndrome (PCOS). This multicenter prospective randomized placebo-controlled blinded study enrolled 393 patients with PCOS at tertiary care sites. Participants were randomized to placebo or troglitazone (150 mg/d, 300 mg/d, or 600 mg/d). At baseline (n = 393) and after 44 weeks of treatment (n = 284) the proportion of normal menstrual cycles, the free testosterone (T) level, four objective measures of facial hair growth (hair density and hair growth rate by photography, and hair diameter and hair growth rate using plucked hairs), and a subjective assessment of the degree of hirsutism, the modified Ferriman-Gallwey (F-G) score, were determined. At both visits, patients also completed the PCOSQ. Since the trial was conducted, troglitazone has been removed from the market because of toxic effects. The PCOSQ includes 26 questions (items) that address five areas of concern (domains), including emotions, body hair, body weight, fertility, and menstruation rated on a seven-point scales in which lower scores denote higher degrees of patient concern and a lower HRQOL. Cronbach's α was >0.7 for four of five domains. Factor analysis provided moderate to strong support for the five-domain structure of the PCOSQ. Cross-sectional correlations were weak with all measures but the F-G score and hair growth (r = -.46, P <. 01). The change in the F-G score showed a statistically significant (P <. 01) correlation with changes in PCOSQ hair growth (r = -.22), weight (r = -.17), infertility (r = -.20), and menstruation (r = -.20). Changes in the proportion of normal menstrual cycles correlated with change in the infertility domain (r =. 14, P <. 03) and with the change in the menstruation domain (r =. 31, P <. 001). The PCOSQ proved as responsive as the F-G, and more responsive than the objective measures of hair growth, to effects of troglitazone. Our data provides some support for the discriminative and longitudinal validity, and appreciable support for the responsiveness, of the PCOSQ.

KW - Health-related quality of life

KW - Quality of life

KW - polycystic ovary syndrome

KW - questionnaire

UR - http://www.scopus.com/inward/record.url?scp=11144327525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144327525&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2003.10.018

DO - 10.1016/j.jclinepi.2003.10.018

M3 - Article

VL - 57

SP - 1279

EP - 1287

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 12

ER -